Cancer still is a major global health issue
According to the International Agency for Research on Cancer (IARC), in 2020, the number of new registered cases surpassed 19.2 M globally, whereas over 9.9 M deaths were attributed to this disease [1]. Despite all the recent breakthroughs in cancer treatments, it is estimated that by 2040, the number of new registered cases and fatalities per year will increase to 30.2 M and 16.3 M, respectively [2, 3]. One of the main reasons cancer still has such a high mortality rate is due to the current lack of tests with the required sensitivity and specificity to aid in the early diagnosis of the disease.
Even though there currently exists multiple cell sorting methods, such as fluorescent-activated cell sorting, magnetic-activated cell sorting, fluorescent-activated droplet sorting, and density gradient centrifugation, these are not compatible with whole blood samples and/or do not have the sufficient sensitivity and specificity to correctly isolate CTCs from blood, which have prevented the development of assays with potential clinical utility… until now.
Welcome to the next generation of cancer blood tests.
Delee has developed a patent pending technology capable of efficiently isolating and analyzing circulating tumor cells from blood, which could dramatically increase the information that physicians have for detecting cancer at early stages and monitoring the applied treatments’ effectiveness.
Achievements
Delee has a patent pending technology that is already fully functional
Delee is running clinical studies for prostate and breast cancer
Our company has a multidisciplinary team of scientists and engineers
We are backed by Y Combinator, StartX, and Emles Venture Partners
Delee is going to start sales as a research use only device by Q4 of 2022
Delee has secured 11 LOIs worth a potential value of over $2.5M USD
The clinical market for CTCs has a TAM of $543B USD